Spinal implant developer L&K Biomed announced on November 17 that it recorded consolidated sales of 10.1 billion KRW, operating profit of 300 million KRW, and net profit of 2.6 billion KRW in the third quarter of this year.
L&K Biomed continued to deliver solid results this year, driven by increased sales of its core spinal implant product line and the addition of new sales from its pectus excavatum implant product line, "Pactus." The company also attributed its performance to securing new clients and actively pursuing overseas sales and marketing efforts.
Looking at cumulative results for the third quarter by country, sales in the United States rose by 12.5% compared to the same period last year. Sales in Thailand and Vietnam also increased by 32% and 100%, respectively. L&K Biomed's strategy to expand into overseas markets and its locally tailored sales activities are yielding positive outcomes.
The decrease in operating profit compared to the same period last year was due to increased personnel and facility investments as the company prepared contracts with major overseas partners. While costs rose, the company explained that these were strategic investments aimed at establishing a foundation for mid- to long-term growth.
L&K Biomed recently prepared for a supply contract with a major global company, with an inspection team visiting the L&K Biomed Yongin plant from November 13 to 14. The team conducted a thorough inspection of the company's overall systems, including product development, manufacturing processes, and quality control. A company representative stated, "We have completed the inspection of production and processes," adding, "We will pursue additional inquiries and meetings from various angles and focus on finalizing the quality agreement and securing the final contract."
L&K Biomed has obtained U.S. Food and Drug Administration (FDA) approval for products such as the first domestic cervical screw and expandable height cage. The company expects a favorable outcome from the quality inspection, based on its extensive experience in international system certification, audits, and issuance of certificates.
L&K Biomed expects to swiftly conclude the quality agreement and move on to the main contract negotiation stage. Joint collaboration with the major company will begin with the U.S. headquarters and will be carried out sequentially with branches in Southeast Asia, Europe, and other countries around the world.
A representative from L&K Biomed stated, "The global major company's inspection team thoroughly reviewed our state-of-the-art production facilities and rigorous quality management system, and engaged in in-depth discussions regarding future collaboration." The representative added, "L&K Biomed possesses all three core elements: manufacturing capability, product competitiveness, and human resources, and we will make every effort to secure the contract."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
